JP2009500037A - Ｈａｅｍｏｐｈｉｌｕｓｉｎｆｌｕｅｎｚａｅ誘発性疾患のためのキメラワクチン - Google Patents

Ｈａｅｍｏｐｈｉｌｕｓｉｎｆｌｕｅｎｚａｅ誘発性疾患のためのキメラワクチン Download PDF

Info

Publication number
JP2009500037A
JP2009500037A JP2008520357A JP2008520357A JP2009500037A JP 2009500037 A JP2009500037 A JP 2009500037A JP 2008520357 A JP2008520357 A JP 2008520357A JP 2008520357 A JP2008520357 A JP 2008520357A JP 2009500037 A JP2009500037 A JP 2009500037A
Authority
JP
Japan
Prior art keywords
seq
protein
nthi
chimeric protein
pila
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008520357A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009500037A5 (https=
Inventor
ローレン オー． バカレッツ，
ロバート エス． ジュニア マンソン，
Original Assignee
ネイションワイド チルドレンズ ホスピタル， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ネイションワイド チルドレンズ ホスピタル， インコーポレイテッド filed Critical ネイションワイド チルドレンズ ホスピタル， インコーポレイテッド
Publication of JP2009500037A publication Critical patent/JP2009500037A/ja
Publication of JP2009500037A5 publication Critical patent/JP2009500037A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1242—Gram-negative bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2008520357A 2005-07-08 2006-07-05 Ｈａｅｍｏｐｈｉｌｕｓｉｎｆｌｕｅｎｚａｅ誘発性疾患のためのキメラワクチン Pending JP2009500037A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69764205P 2005-07-08 2005-07-08
US80183506P 2006-05-19 2006-05-19
PCT/US2006/026183 WO2007008527A2 (en) 2005-07-08 2006-07-05 Chimeric vaccine for haemophilus influenzae-induced disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009237768A Division JP2010172332A (ja) 2005-07-08 2009-10-14 Ｈａｅｍｏｐｈｉｌｕｓｉｎｆｌｕｅｎｚａｅ誘発性疾患のためのキメラワクチン

Publications (2)

Publication Number Publication Date
JP2009500037A true JP2009500037A (ja) 2009-01-08
JP2009500037A5 JP2009500037A5 (https=) 2010-01-14

Family

ID=37441871

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008520357A Pending JP2009500037A (ja) 2005-07-08 2006-07-05 Ｈａｅｍｏｐｈｉｌｕｓｉｎｆｌｕｅｎｚａｅ誘発性疾患のためのキメラワクチン
JP2009237768A Pending JP2010172332A (ja) 2005-07-08 2009-10-14 Ｈａｅｍｏｐｈｉｌｕｓｉｎｆｌｕｅｎｚａｅ誘発性疾患のためのキメラワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009237768A Pending JP2010172332A (ja) 2005-07-08 2009-10-14 Ｈａｅｍｏｐｈｉｌｕｓｉｎｆｌｕｅｎｚａｅ誘発性疾患のためのキメラワクチン

Country Status (7)

Country Link
US (3) US7811591B2 (https=)
EP (2) EP2298794A3 (https=)
JP (2) JP2009500037A (https=)
AT (1) ATE488526T1 (https=)
CA (1) CA2613970C (https=)
DE (1) DE602006018308D1 (https=)
WO (1) WO2007008527A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014512365A (ja) * 2011-04-13 2014-05-22 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム インフルエンザ菌タンパク質ｅおよびピリンａを含む融合タンパク質および組合せワクチン
JP2015536312A (ja) * 2012-10-17 2015-12-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム １種以上の肺炎球菌莢膜糖類コンジュゲートとインフルエンザ菌由来のタンパク質Ｅおよび／またはＰｉｌＡを含むタンパク質成分とを含む免疫原性組成物

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9812613D0 (en) * 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
DE602006018308D1 (de) * 2005-07-08 2010-12-30 Nationwide Childrens Hospital Chimärer impfstoff für haemophilus influenzae-induzierte infektion
GB201218660D0 (en) 2012-10-17 2012-11-28 Glaxosmithkline Biolog Sa Immunogenic composition
US9855326B2 (en) 2013-03-08 2018-01-02 Research Institute At Nationwide Children's Hospital Transcutaneous haemophilus influenzae vaccine formulations and methods
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
US11248040B2 (en) 2013-09-26 2022-02-15 Trellis Bioscience, Llc Binding moieties for biofilm remediation
WO2017011588A1 (en) 2015-07-14 2017-01-19 Research Institute At Nationwide Children's Hospital Novel formulation for the elimination of cariogenic and opportunistic pathogens within the oral cavity
AU2016303688B2 (en) 2015-07-31 2023-06-15 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
WO2017066719A2 (en) 2015-10-14 2017-04-20 Research Institute At Nationwide Children's Hospital Hu specific interfering agents
JP7514621B2 (ja) 2017-01-04 2024-07-11 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル Ｄｎａｂｉｉワクチンおよび強化された活性を有する抗体
SG11202103001PA (en) 2018-10-05 2021-04-29 Res Inst Nationwide Childrens Hospital Hmgb1 protein derivatives for the removal of biofilms cross-reference to related application
CN112961242B (zh) * 2020-06-30 2022-01-04 广州百暨基因科技有限公司 抗b7h3抗体及其应用
US12116614B2 (en) 2020-06-30 2024-10-15 Research Institute At Nationwide Children's Hospital Methods for determining antibiotic sensitivity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843464A (en) * 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US19005A (en) 1857-12-29 de witt
US697642A (en) 1901-03-09 1902-04-15 Liberty Millet Process of strengthening clay hydraulic pipe, vases, crockery-ware, &c.
US801835A (en) 1905-02-25 1905-10-17 Rudolph H Apelt Ball-bearing.
US1900504A (en) 1930-11-25 1933-03-07 Ingersoll Rand Co Condensing apparatus
ES2185658T3 (es) * 1993-05-18 2003-05-01 Univ Ohio State Res Found Vacuna para la otitis media.
DE4336530C1 (de) * 1993-10-26 1995-04-13 Max Planck Gesellschaft Rekombinante PilC-Proteine, Verfahren zu ihrer Herstellung und ihre Verwendung
US6355450B1 (en) * 1995-04-21 2002-03-12 Human Genome Sciences, Inc. Computer readable genomic sequence of Haemophilus influenzae Rd, fragments thereof, and uses thereof
GB9812613D0 (en) * 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
PL1697403T3 (pl) * 2003-12-23 2010-09-30 Nationwide Childrens Hospital Inc Pilusy typu IV Haemophilus influenzae
DE602006018308D1 (de) * 2005-07-08 2010-12-30 Nationwide Childrens Hospital Chimärer impfstoff für haemophilus influenzae-induzierte infektion

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843464A (en) * 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014512365A (ja) * 2011-04-13 2014-05-22 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム インフルエンザ菌タンパク質ｅおよびピリンａを含む融合タンパク質および組合せワクチン
US11198707B2 (en) 2011-04-13 2021-12-14 Glaxosmithkline Biologicals Sa Fusion proteins and combination vaccines comprising Haemophilus influenzae Protein E and Pilin A
JP2015536312A (ja) * 2012-10-17 2015-12-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム １種以上の肺炎球菌莢膜糖類コンジュゲートとインフルエンザ菌由来のタンパク質Ｅおよび／またはＰｉｌＡを含むタンパク質成分とを含む免疫原性組成物

Also Published As

Publication number Publication date
WO2007008527A2 (en) 2007-01-18
EP1904519B1 (en) 2010-11-17
EP2298794A2 (en) 2011-03-23
US20130064828A1 (en) 2013-03-14
US20080311110A1 (en) 2008-12-18
JP2010172332A (ja) 2010-08-12
US20110081357A1 (en) 2011-04-07
US8263363B2 (en) 2012-09-11
EP1904519A2 (en) 2008-04-02
WO2007008527A3 (en) 2007-03-15
DE602006018308D1 (de) 2010-12-30
US8741304B2 (en) 2014-06-03
CA2613970A1 (en) 2007-01-18
US7811591B2 (en) 2010-10-12
CA2613970C (en) 2015-12-08
ATE488526T1 (de) 2010-12-15
EP2298794A3 (en) 2011-04-06

Similar Documents

Publication Publication Date Title
JP2010172332A (ja) Ｈａｅｍｏｐｈｉｌｕｓｉｎｆｌｕｅｎｚａｅ誘発性疾患のためのキメラワクチン
JP5616766B2 (ja) ＨａｅｍｏｐｈｉｌｕｓｉｎｆｌｕｅｎｚａｅＩＶ型ピリ線毛
JP2009142276A (ja) モラクセラ・カタラーリスのｕｓｐａ１及びｕｓｐａ２抗原
JP2002517218A (ja) ワクチン
KR20140017554A (ko) 폐렴 구균에 대한 백신 및 조성물
JP2009500037A5 (https=)
US9249199B2 (en) Synthetic Streptococcus pneumoniae vaccine
US9267947B2 (en) Compositions and methods for preventing or treating Burkholderia infection
JP4236215B2 (ja) 非型性のヘモフイルス インフルエンザ（Ｈａｅｍｏｐｈｉｌｕｓ ｉｎｆｌｕｅｎｚａｅ）株用のワクチンとしての精製非型性ヘモフイルス インフルエンザＰ５蛋白質
US12048740B2 (en) Transcutaneous dosage formulation
JP2001514894A (ja) ナイセリア・ラクトフェリン結合プロテイン
JP6401148B2 (ja) 抗原および抗原の組み合わせ
US8501197B2 (en) Compositions and methods for stimulating immune response against Moraxella catarrhalis
ES2356077T3 (es) Vacuna quimérica para una enfermedad inducida por haemophilus influenzae.
US20140199350A1 (en) Chimeric topical vaccine for haemophilus influenzae-induced disease
AU2012203017B2 (en) Haemophilus Influenzae Type IV Pili
NZ615328A (en) Fusion proteins and combination vaccines comprising haemophilus influenzae protein e and pilin a

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090625

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090625

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20091014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100616

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110921

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111220

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120312